Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>STAAR Surgical recently reported its first-quarter 2025 financial results, which reflected a period of strategic transition aimed at addressing various challenges and positioning the company for long-term growth.</li><li>The company's revenue for the quarter stood at $42.6 million, a significant decline from the $77.4 million recorded in the same period last year.</li><li>This decrease was mainly attributed to minimal purchases by STAAR’s China distributors as they managed through existing inventory, though this was partially offset by growth in sales outside China.</li></ul>

STAAR Surgical recently reported its first-quarter 2025 financial results, which reflected a period of strategic transition aimed at addressing various challenges and positioning the company for long-term growth.The company's revenue for the quarter stood at $42.6 million, a significant decline from the $77.4 million recorded in the same period last year.This decrease was mainly attributed to minimal purchases by STAAR’s China distributors as they managed through existing inventory, though this was partially offset by growth in sales outside China.

STAAR Surgical: Is Broadwood Quietly Taking Over This Struggling Eye-Tech Stock?

<ul><li>The first quarter of 2024 saw STAAR Surgical achieve a noteworthy result by generating net sales of $77.4 million, surpassing the expectations set for this period.</li><li>This result underscores the effectiveness of STAAR Surgical's refined commercial strategy and the high uptake of its proprietary EVO ICL technology across all key geographical regions.</li><li>With a year-over-year increase represented by these figures, the company successfully navigated the challenges of a market predominantly inclined towards laser vision correction, where it successfully captured additional market share.</li></ul>

The first quarter of 2024 saw STAAR Surgical achieve a noteworthy result by generating net sales of $77.4 million, surpassing the expectations set for this period.This result underscores the effectiveness of STAAR Surgical's refined commercial strategy and the high uptake of its proprietary EVO ICL technology across all key geographical regions.With a year-over-year increase represented by these figures, the company successfully navigated the challenges of a market predominantly inclined towards laser vision correction, where it successfully captured additional market share.

STAAR Surgical Takeover Speculation: 4 Reasons Why We Are Optimistic! - Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

The S&amp;P 500’s 5-month uptrend remains intact, and as long as it continues we remain bullish. With that said, we are near the top end of the uptrend channel and could fall 2.75%-3.25% before we get to uptrend support. Overall we believe the positives outweigh the concerns as highlighted in this week's report.  Also highlighted are actionable names in Retailing, Health Care, and small-cap Aero Defense.

The S&amp;P 500’s 5-month uptrend remains intact, and as long as it continues we remain bullish. With that said, we are near the top end of the uptrend channel and could fall 2.75%-3.25% before we get to uptrend support. Overall we believe the positives outweigh the concerns as highlighted in this week's report.  Also highlighted are actionable names in Retailing, Health Care, and small-cap Aero Defense.

S&P 500 Bullish but Extended; Downgrading Financials

United States

STAAR Surgical Company develops, manufactures, and markets high margin visual implants that improve a patient's quality of vision.  The Company manufactures implantable contact lenses to treat refractive disorders such as myopia.  STAAR also manufactures products for cataract surgery and glaucoma surgery.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Staar Surgical Co (STAA US)

STAAR Surgical: Is Broadwood Quietly Taking Over This Struggling Eye-Tech Stock?

STAAR Surgical recently reported its first-quarter 2025 financial results, which reflected a period of strategic transition aimed at addressing...

Baptista Research

STAAR Surgical Takeover Speculation: 4 Reasons Why We Are Optimistic! - Major Drivers

The first quarter of 2024 saw STAAR Surgical achieve a noteworthy result by generating net sales of $77.4 million, surpassing the expectations set...

Baptista Research

S&P 500 Bullish but Extended; Downgrading Financials

The S&P 500’s 5-month uptrend remains intact, and as long as it continues we remain bullish. With that said, we are near the top end of the...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)